<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613365</url>
  </required_header>
  <id_info>
    <org_study_id>2011-004536-63</org_study_id>
    <secondary_id>2011-24</secondary_id>
    <nct_id>NCT01613365</nct_id>
  </id_info>
  <brief_title>Oropharyngeal and Nasopharyngeal Decontamination With Chlorhexidine Gluconate in the Reduction of the Postoperative Morbidity and Mortality After Major Pulmonary Resections</brief_title>
  <acronym>CHLORHEX</acronym>
  <official_title>Oropharyngeal and Nasopharyngeal Decontamination With Chlorhexidine Gluconate in the Reduction of the Postoperative Morbidity and Mortality After Major Pulmonary Resections: a Multicentric, Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite improvement of per and postoperative management, major pulmonary surgery continues to&#xD;
      carry out a high morbidity with a significant mortality. Among postoperative complications,&#xD;
      respiratory failures (nosocomial pneumonia, ARDS) are currently the most frequent and&#xD;
      serious, as well as being the primary cause of hospital death, after major pulmonary&#xD;
      resections. Vast majority of these complications are notoriously infectious and should be&#xD;
      considered as hospital-acquired infections. These complications result in a dramatic&#xD;
      increased of substantial hospital costs in term of length of hospital stay, antibiotics and&#xD;
      morbidity. Current management of these complications stands on antibiotics, oxygen supply and&#xD;
      physiotherapy. In severe case, a ventilatory support (invasive or non invasive) is justify in&#xD;
      near 25 % of cases.&#xD;
&#xD;
      Recent data have suggested that proximal airways colonizations could be an essential first&#xD;
      step in the pathogenesis of theses respiratory failures. Previous works have long&#xD;
      demonstrated that bacterial colonization was frequent between 21 to 40 % in lung cancer&#xD;
      patients. These colonizations could act as a major predisposing factor to these postoperative&#xD;
      respiratory failures. Because distal airways and lung parenchyma are free from bacteria at&#xD;
      the moment of the surgery, respiratory complications should be the result from contamination&#xD;
      by potential microorganisms belonging the upper aero-digestive tract. Consequently,&#xD;
      decontamination of the oropharyngeal and nasopharyngeal cavities before and during the first&#xD;
      days after surgery could have a beneficial advantage in the prevention of these&#xD;
      complications. This decontamination has been demonstrated to be effective in critically-ill&#xD;
      patients in intensive care unit, in cardiac surgery and in esophageal surgery.&#xD;
      Decontamination of oropharynx and nasopharynx with Chlorhexidine Gluconate has significantly&#xD;
      reduced the rate of postoperative global hospital-acquired infections and respiratory&#xD;
      infectious as well. To date, data on the efficacy of this decontamination protocol in major&#xD;
      pulmonary resections are not available.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients requiring ventilatory support</measure>
    <time_frame>36 MONTHS</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>occurrence of documented hospital-acquired respiratory infections</measure>
    <time_frame>36 MONTHS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence of documented non-respiratory hospital-acquired infections</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">474</enrollment>
  <condition>Infections and Respiratory Infectious</condition>
  <arm_group>
    <arm_group_label>chlorhexidine gluconate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine Gluconate</intervention_name>
    <description>Oropharyngeal and nasopharyngeal decontamination with Chlorhexidine Gluconate</description>
    <arm_group_label>chlorhexidine gluconate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oropharyngeal and nasopharyngeal decontamination with placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult men and women over 18 years&#xD;
&#xD;
          -  Submitted to major pulmonary resections for primary lung cancer or pulmonary&#xD;
             metastasis&#xD;
&#xD;
          -  Anatomical resections (segmentectomy, lobectomy, pneumonectomy)&#xD;
&#xD;
          -  With mediastinal lymph node dissection.&#xD;
&#xD;
          -  Patient fit for operation&#xD;
&#xD;
          -  After informed consent&#xD;
&#xD;
        Non inclusion criteria:&#xD;
&#xD;
          -  Patients &lt; 18 years&#xD;
&#xD;
          -  Pulmonary infectious lesions&#xD;
&#xD;
          -  Recent respiratory infections&#xD;
&#xD;
          -  Tracheostomy&#xD;
&#xD;
          -  Swallow difficulties&#xD;
&#xD;
          -  Need for non-invasive ventilation before surgery&#xD;
&#xD;
          -  Documented sensibility to Chlorhexidine&#xD;
&#xD;
          -  Previous ENT cancer&#xD;
&#xD;
          -  Previous thoracic surgery&#xD;
&#xD;
          -  Patients with an oral assessment score (OAG) &gt;9&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BERNARD BELAIGUES</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique h√¥pitaux de Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>D'JOURNO BENOIT</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP HM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>June 5, 2012</study_first_submitted>
  <study_first_submitted_qc>June 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <last_update_submitted>August 6, 2015</last_update_submitted>
  <last_update_submitted_qc>August 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

